Investigational Drug Details
| Drug ID: | D159 |
| Drug Name: | Green Cardamom |
| Synonyms: | Elettaria Cardamomum |
| Type: | Herbal medicine |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (IRCT2015121317254N4) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0857 | IRCT2015121317254N4 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 27/12/2015 | 22 February 2018 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A11494 | 30871514 | BMC Complement Altern Med | Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial. | Details |
| A12831 | 30263038 | Nutr Metab (Lond) | Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. | Details |
| A16054 | 28592311 | Trials | The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. | Details |
| A19756 | 26378573 | Nutrients | Green and Black Cardamom in a Diet-Induced Rat Model of Metabolic Syndrome. | Details |